Bioxcel therapeutics reports first quarter 2023 financial results and recent operational highlights

Igalmi™ (dexmedetomidine) commercial momentum accelerating with doubling of formulary wins, unlocking more than $55 million in targeted market opportunity, and an additional $255 million scheduled to vote

BTAI Ratings Summary

BTAI Quant Ranking